Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07562581CT.gov A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07643350CT.gov Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07294261CT.gov Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07231575CT.gov Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06977828CT.gov A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06945705CT.gov A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis | — | Recruiting | — | — | — |
NCT06851169CT.gov This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response | — | Not Yet Recruiting | — | — | — |
NCT06634667CT.gov Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | — | Not Yet Recruiting | — | — | — |
NCT06348927CT.gov Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC | — | Recruiting | — | — | — |
NCT06476093CT.gov SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 95 more trialsShow fewer
NCT06356675CT.gov A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy | — | Not Yet Recruiting | — | — | — |
NCT06355609CT.gov Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW | — | Recruiting | — | — | — |
NCT06352008CT.gov To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06475755CT.gov Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06379087CT.gov Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC | — | Recruiting | — | — | — |
NCT06221462CT.gov Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06341530CT.gov Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT06182761CT.gov A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07037680CT.gov Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT | — | Recruiting | — | — | — |
NCT06188650CT.gov The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study | — | Recruiting | — | — | — |
NCT06277674CT.gov Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | — | Unknown | — | — | — |
NCT06102928CT.gov A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation | — | Recruiting | — | — | — |
NCT05913089CT.gov A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05842018CT.gov Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) | — | Unknown | — | — | — |
NCT06141226CT.gov Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05778149CT.gov Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | — | Not Yet Recruiting | — | — | — |
NCT05816499CT.gov Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT05715398CT.gov BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05271916CT.gov First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | — | Recruiting | — | — | — |
NCT05485350CT.gov Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT05387109CT.gov Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05460481CT.gov Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | — | Unknown | — | — | — |
NCT05319886CT.gov Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients | — | Unknown | — | — | — |
NCT05306847CT.gov Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05481775CT.gov Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05218759CT.gov Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC | — | Unknown | — | — | — |
NCT05346952CT.gov A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | — | Unknown | — | — | — |
NCT05460195CT.gov Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation | — | Unknown | — | — | — |
NCT04136535CT.gov Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT04895930CT.gov Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC | — | Unknown | — | — | — |
NCT05021328CT.gov Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | — | Completed | — | — | — |
NCT04846634CT.gov Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) | — | Not Yet Recruiting | — | — | — |
NCT04967079CT.gov Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | — | Completed | — | — | — |
NCT04846452CT.gov Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | — | Unknown | — | — | — |
NCT04978753CT.gov the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04797806CT.gov Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC | — | Unknown | — | — | — |
NCT04691388CT.gov A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor | — | Completed | — | — | — |
NCT04762030CT.gov Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study | — | Unknown | — | — | — |
NCT04770688CT.gov Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib | — | Completed | — | — | — |
NCT04646330CT.gov A Trial of AK104 Plus Anlotinib in NSCLC | — | Completed | — | — | — |
NCT04958993CT.gov A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04619563CT.gov A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT04507906CT.gov Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | — | Completed | — | — | — |
NCT04619537CT.gov A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04544644CT.gov A Study of Combination Therapy in NSCLC | — | Unknown | — | — | — |
NCT04273815CT.gov A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | — | Unknown | — | — | — |
NCT04453423CT.gov Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | — | Unknown | — | — | — |
NCT04325763CT.gov A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | — | Unknown | — | — | — |
NCT04358562CT.gov Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | — | Unknown | — | — | — |
NCT04316351CT.gov Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance | — | Unknown | — | — | — |
NCT04313660CT.gov Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | — | Unknown | — | — | — |
NCT04322617CT.gov Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer | — | Recruiting | — | — | — |
NCT04211896CT.gov Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04181372CT.gov A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | — | Unknown | — | — | — |
NCT04164745CT.gov Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04165330CT.gov Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04111913CT.gov A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04124731CT.gov Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE) | — | Unknown | — | — | — |
NCT04439890CT.gov A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04029350CT.gov Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M | — | Unknown | — | — | — |
NCT04007835CT.gov Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI | — | Unknown | — | — | — |
NCT03769805CT.gov Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC | — | Unknown | — | — | — |
NCT03910127CT.gov Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | — | Unknown | — | — | — |
NCT04012619CT.gov Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer | — | Completed | — | — | — |
NCT03743129CT.gov Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） | — | Completed | — | — | — |
NCT04028778CT.gov Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC | — | Unknown | — | — | — |
NCT03766490CT.gov Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03790228CT.gov Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC | — | Unknown | — | — | — |
NCT03998085CT.gov Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC | — | Unknown | — | — | — |
NCT03799601CT.gov Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC | — | Unknown | — | — | — |
NCT03778853CT.gov Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006) | — | Unknown | — | — | — |
NCT03778138CT.gov Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC | — | Unknown | — | — | — |
NCT03726736CT.gov Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC | — | Unknown | — | — | — |
NCT03736837CT.gov Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC | — | Completed | — | — | — |
NCT03750916CT.gov Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03755869CT.gov Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020） | — | Unknown | — | — | — |
NCT03866980CT.gov A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03768037CT.gov Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC | — | Unknown | — | — | — |
NCT03765775CT.gov Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | — | Unknown | — | — | — |
NCT03735264CT.gov Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） | — | Unknown | — | — | — |
NCT03732001CT.gov A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC | — | Unknown | — | — | — |
NCT03672136CT.gov Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | — | Unknown | — | — | — |
NCT03728374CT.gov Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | — | Unknown | — | — | — |
NCT03624309CT.gov Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer | — | Unknown | — | — | — |
NCT03671538CT.gov Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | — | Unknown | — | — | — |
NCT03654027CT.gov Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC | — | Unknown | — | — | — |
NCT03636685CT.gov Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | — | Unknown | — | — | — |
NCT03646968CT.gov Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study | — | Unknown | — | — | — |
NCT03602027CT.gov Phase I Study of the Combination of Anlotinib With Gefitinib | — | Unknown | — | — | — |
NCT03566576CT.gov Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel | — | Unknown | — | — | — |
NCT04670107CT.gov The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy | — | Completed | — | — | — |
NCT03461185CT.gov Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02388919CT.gov Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303） | — | Completed | — | — | — |
NCT02029209CT.gov To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT01924195CT.gov Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302） | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Catequentinib (this asset) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Approved | B · 63 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Catequentinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P3 | BB · 70 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BB · 66 |
| Kidney Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Catequentinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/catequentinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →